Redeye retains its positive view on Sdiptech following a Q1 report in line with our expectations. While leaving our organic forecasts largely unchanged, we lower our Base Case following a higher WACC due to an increased risk-free rate.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/